Publications
The Research
Behind Gavia BIO
Gavia BIO's technology, Minneganan (DGL13K) is built upon years of University of Minnesota research into antimicrobial peptides, bacterial resistance and novel therapeutic development.
Below is a growing collection of our peer-reviewed publications and related scientific resources that have shaped our approach to combating antimicrobial resistance.
Targeted Modification of the Antimicrobial Peptide DGL13K Reveals a Naturally Optimized Sequence for Topical Applications.
Gorr, S.-U. Microorganisms, 13:10 (2025)
Resisting the resistance: the antimicrobial peptide DGL13K selects for small colony variants of Staphylococcus aureus that show increased resistance to its stereoisomer LGL13K, but not to DGL13K.
Gorr S-U. Journal of Bacteriology 207:e00505–24 (2025).
The oral pathogen Porphyromonas gingivalis gains tolerance to the antimicrobial peptide DGL13K by synonymous mutations in hagA.
Gorr SU, Chen R, Abrahante JE, Joyce PBM. PLoS One 19: e0312200 (2024).
The Antimicrobial Peptide DGL13K Is Active against Drug-Resistant Gram-Negative Bacteria and Sub-Inhibitory Concentrations Stimulate Bacterial Growth without Causing Resistance.
Gorr, S. U., H. V. Brigman, J. C. Anderson, and E. B. Hirsch. PLoS One 17, no. 8 (2022): e0273504
In vivo activity and low toxicity of the second-generation antimicrobial peptide DGL13K
S. U. Gorr, C. M. Flory and R. J. Schumacher, PLoS One 14: e0216669 (2019).
A D-Enantiomer of the Antimicrobial Peptide GL13K Evades Antimicrobial Resistance in the Gram Positive Bacteria Enterococcus Faecalis and Streptococcus Gordonii.
Hirt, H., J. W. Hall, E. Larson, and S. U. Gorr. PLoS One 13, no. 3 (2018): e0194900.
Antimicrobial Peptide GL13K Is Effective in Reducing Biofilms of Pseudomonas Aeruginosa
Hirt, H., and S. U. Gorr. Antimicrobial Agents & Chemotherapy 57, no. 10 (Oct 2013): 4903–10.